Actinium-225 is an isotope of actinium. It undergoes alpha decay to francium-221 with a half-life of 10 days, and is an intermediate decay product in the neptunium series. From Wikipedia
Enrollment for the TRACY-1 trial is underway at Mayo Clinic’s three campuses alongside roughly 20 other U.S. sites following the initial actinium-225 dose.
